Last reviewed · How we verify
dual target CAR-T cell therapy
dual target CAR-T cell therapy is a Biologic drug developed by YuLi. It is currently in Phase 1 development.
At a glance
| Generic name | dual target CAR-T cell therapy |
|---|---|
| Sponsor | YuLi |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LYL314 in Aggressive Large B-Cell Lymphoma (PHASE1, PHASE2)
- Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis (PHASE1)
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (PHASE2)
- CAR-T Followed by Bispecific Antibodies (PHASE2)
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (PHASE3)
- A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (PHASE1)
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dual target CAR-T cell therapy CI brief — competitive landscape report
- dual target CAR-T cell therapy updates RSS · CI watch RSS
- YuLi portfolio CI
Frequently asked questions about dual target CAR-T cell therapy
What is dual target CAR-T cell therapy?
dual target CAR-T cell therapy is a Biologic drug developed by YuLi.
Who makes dual target CAR-T cell therapy?
dual target CAR-T cell therapy is developed by YuLi (see full YuLi pipeline at /company/yuli).
What development phase is dual target CAR-T cell therapy in?
dual target CAR-T cell therapy is in Phase 1.
Related
- Manufacturer: YuLi — full pipeline
- Compare: dual target CAR-T cell therapy vs similar drugs
- Pricing: dual target CAR-T cell therapy cost, discount & access